We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury.
Clinical trial NCT06001294 · UNKNOWN
Trial details
- NCT number
- NCT06001294
- Sponsor
- Xiangcheng Zhang
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2022-07-03
- Primary completion
- 2023-12-31
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.